Pharma BD Deal Intelligence
Inhale paid ~$200M in cash and stock for Bradford's supercritical-fluid particle technology, then shut the entire UK site five years later, publicly stating the tech didn't fit its strategy — one licensed spinout asset aside, the acquisition was effectively abandoned.
Full analysis, sources & comparables →Inhale Therapeutic Systems offered $20M cash plus 3.75M shares (~$200M total) for Bradford Particle Design, calling SEDS the leading supercritical-fluid…
The University of Bradford will be £36 million richer today after selling its share of spin-off Bradford Particle Design to Inhale for £200 million in cash and…
BPD was acquired by Inhale Therapeutic Systems in January 2001; the SEDS platform was widely regarded as the industry's leader in supercritical-fluid particle…
Source summaries from our enrichment pipeline; follow links for originals.
All 5 sources with sentiment breakdown →
$20M cash plus 3.75M Inhale shares (~$200M total). Supercritical-fluid particle engineering; pulmonary drug delivery.
Inhale paid ~$200M in cash and stock for Bradford's supercritical-fluid particle technology, then shut the entire UK site five years later, publicly stating the tech didn't fit its strategy — one licensed spinout asset aside, the acquisition was effectively abandoned.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Inhale Therapeutic Systems Inc. / Bradford Particle Design plc (UK) (this deal) | 2001 | $200M | 14 |
| Inhale Therapeutic Systems Inc. / Shearwater Corporation | 2001 | $192M | 73 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals